OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Oncology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Harnessing dendritic cells for innovative therapeutic cancer vaccines	58
Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint?	39
Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy	36
Content features and its implementation in novel app-based psycho-oncological interventions for cancer survivors: a narrative review	30
First and further-line multidisciplinary treatment of retroperitoneal sarcomas	29
Progress in diagnosis and treatment of checkpoint inhibitor pneumonitis	28
Editorial introductions	25
Neurorehabilitation in brain tumours: evidences and suggestions for spreading of knowledge and research implementation	22
State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies	21
Collecting information from all sarcoma reference cancer centres worldwide: achievement and next steps	21
Psycho-oncology interventions focusing on fatigue and sleep disturbances	21
Role of PSMA PET/CT in imaging and management of prostate cancer	19
The role of signaling lymphocyte activation molecule family receptors in hematologic malignancies	18
Epigenetic dynamics of aging and cancer development: current concepts from studies mapping aging and cancer epigenomes	17
Importance of guidelines and networking for the management of rare gynecological cancers	16
Editorial introductions	16
Impact of sentinel node use in lymphedema formation among gynecologic cancer patients	16
Treatments and challenges in advanced prostate cancer	16
Beyond ‘the good, the bad and the ugly’: let us put rectal cancer patients at the centre of the decision making	15
State-of-the-art and trends in fibroblast growth factor receptor-directed therapies in gastro-intestinal malignancies	15
Neoadjuvant and adjuvant approaches in gastroesophageal cancers	15
WHO 2021 and beyond: new types, molecular markers and tools for brain tumor classification	14
How to prevent human papillomavirus-related oropharyngeal cancer?	14
New hopes in relapsed refractory primary central nervous system lymphoma	13
Local treatment in patients with hereditary breast cancer: decision-making process in low-, moderate-, high-penetrance pathogenic germline mutation carriers	12

Editorial introductions	12
Biomarkers and immunotherapy: where are we?	12
Tropomyosin receptor kinases in sarcomas – of joy and despair	12
Pregnancy-related hormonal changes and thyroid growth: do they have an impact on the higher incidence of differentiated thyroid cancer in women?	11
Safety of assisted reproductive techniques in gynecological cancer patients	11
Enhancing proactive life-sustaining treatment preference documentation in advanced cancer care: barriers and recommendations	11
Can we yet use tertiary lymphoid structures as predictive biomarkers for immunotherapy response in melanoma?	11
Dyadic psychosocial interventions for patients with cancer and their caregivers: an update	11
Gynecological sarcomas: literature review of 2020	10
Controversies in central nervous system prophylaxis of high-risk diffuse large B-cell lymphoma	10
Melanoma with genetic alterations beyond the BRAF V600 mutation: management and new insights	10
A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in treating patients with different types of thyroid cancer: how to choose drugs appropriately?	10
Editorial introductions	10
Recent advances in precision medicine for acute myeloid leukemia	10
State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies	10
Immunomodulation for hepatocellular carcinoma therapy: current challenges	9
Interventions aiming to improve advance care planning uptake in oncology: a scoping review of recent randomized controlled trials	9
Circulating tumor DNA in breast cancer: a biomarker for patient selection	9
Current evidence of integrative oncology modalities for managing adverse effects and survivorship issues among adolescents and young adult (AYA) cancer patients and survivors	9
Liquid biopsy in brain tumors: moving on, slowly	9
Lung cancer screening in never smokers	9
Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results	8
New developments in rare vulvar and vaginal cancers	8
Antibody–drug conjugates in rare genitourinary tumors: review and perspectives	8
Editorial: Lung cancer: continuous progress in diagnosis and treatment	8
How to become a Multinational Association of Supportive Care in Cancer-designated center of excellence in supportive care in cancer	8
Pathology and new insights in central nervous system lymphomas	8
Editorial introductions	8
Antibodies targeting Prostate-Specific Membrane Antigen positive prostate cancer: from diagnostic imaging to theranostics	7
Hybrid magnetic resonance and PET imaging for prostate cancer recurrence	7
The changing landscape for patients with relapsed/refractory acute myeloid leukaemia	7
Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients	7
Editorial introductions	7
Primary vitreoretinal lymphoma: short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up	7
The role of genetic testing in prostate cancer screening, diagnosis, and treatment	7
The 5T's of health disparities in multiple myeloma in Latin America	7
Mind the target: programmed death ligand 1 in oesophagogastric cancers	6
Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations	6
The path to personalized treatment in advanced and metastatic biliary tract cancers: a review of new targeted therapies and immunotherapy	6
Editorial introductions	6
Controversies on chemotherapy for early HR+/HER2− breast cancer: the role of anthracyclines and dose intensification	6
Editorial introductions	6
A new comprehensive and stratified concept for supportive care in cancer patients	6
Machine learning applications and challenges in graft-versus-host disease: a scoping review	6
Editorial introductions	6
State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies	6
Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results	6
How to support parenting in patients with cancer and co-parents? From research to practice	6
Desmoid tumors: who, when and how to treat?	6
Editorial introductions	6

Less is more in endometrial cancer (SLN, conservative treatment, radical hysterectomy, molecular classification)	6
Potential application of artificial intelligence in cancer therapy	6
Breast surgery after neoadjuvant therapy	6
Advances in the pathogenesis of FLT3-mutated acute myeloid leukemia and targeted treatments	5
Current status of phosphoinotiside-3 kinase inhibitors in blood cancers	5
What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?	5
HER2-positive breast cancer: cotargeting to overcome treatment resistance	5
Pathologic diagnosis of lung cancer – recent developments	5
Editorial introductions	5
Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer	5
Clinical management of brain tumors in pregnancy	5
How to treat localized Hodgkin lymphoma?	5
Immunotherapies in non-metastatic gastrointestinal cancers	5
Adjuvant and neoadjuvant approaches in pancreatic cancer	5
Targeting cancer stem cell pathways for lung cancer therapy	5
Sarcoma incidence worldwide: regional differences in histology and molecular subtypes	5
Treatment of radiation-associated angiosarcoma	5
Question prompt lists to improve communication between cancer patients and healthcare professionals	5
Thinking through the multimodal treatment of localized oesophageal cancer: the point of view of the surgeon	5
Neoadjuvant immune checkpoint blockade enhances local and systemic tumor immunity in head and neck cancer	5
How to monitor the side effects of treatments in cancer patients	5
Targeting SUMOylation in cancer	5
When do I ask for a DNA methylation array for primary brain tumor diagnosis?	5
Preclinical glioma models in neuro-oncology: enhancing translational research	5